Amphotericin B in Pediatrics: Analysis by Age Stratification Suggests a Greater Chance of Adverse Events from 13 Months of Age Onwards.
Francelise Bridi CavassinJoão Luiz Baú-CarneiroFábio Araújo MottaAna Paula Matzenbacher VilleLeticia StaszczakFlávio de Queiroz TellesPublished in: Paediatric drugs (2022)
Clinical or observational studies based on age stratification are essential to accurately elucidate whether potentially toxic drugs can be used safely in the pediatric population. Our search for a turning point was shown to contribute to the accuracy of the study, as it provided data on the impact of D-AMB in specific pediatric age groups.